[
    {
        "title": "Gunawardhana L, Becker MA, Whelton A, et al. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis research & therapy 2018; 20: 99.",
        "paper_uid": "fe64e910",
        "pmid": "29848361",
        "reference": "Gunawardhana L, Becker MA, Whelton A, et al. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis research & therapy 2018; 20: 99.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Saag KG, Whelton A, Becker MA, et al. Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis and Rheumatology 2016; 68: 2035-2043.",
        "paper_uid": "952f807d",
        "pmid": "26894653",
        "reference": "Saag KG, Whelton A, Becker MA, et al. Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis and Rheumatology 2016; 68: 2035-2043.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Tanaka K, Nakayama M, Kanno M, et al. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clinical and experimental nephrology 2015; 19: 1044\u20101053.",
        "paper_uid": "d648e2a1",
        "pmid": "25676011",
        "reference": "Tanaka K, Nakayama M, Kanno M, et al. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clinical and experimental nephrology 2015; 19: 1044\u20101053.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Wada T, Hosoya T, Honda D, et al. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). Clinical and Experimental Nephrology 2018; 22: 860-870.",
        "paper_uid": "0eea59fb",
        "pmid": "29372470",
        "reference": "Wada T, Hosoya T, Honda D, et al. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). Clinical and Experimental Nephrology 2018; 22: 860-870.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    }
]